Search company, investor...
Endologix company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year



Take Private | Alive

Total Raised


About Endologix

Endologix is a developer and manufacturer of minimally invasive treatments for vascular diseases. Endologix is focusing on the development and marketing of its patented technology for the treatment of Abdominal Aortic Aneurysms (AAA). An aneurysm is a weakening of the wall of the aorta, the largest artery of the body. Aortic aneurysm disease is a cause of death in the United States and it is estimated that 1.7 million persons over 55 years of age have an AAA. Each year, physicians diagnose approximately 200,000 people in the United States with AAA. Endologix is currently marketing its Powerlink Delivery System a, one-piece endoluminal stent graft (ELG) used in treating AAA that has significant advantages when compared with marketed stent alternatives. Powerlink has been commercially available in Europe since 1999. FDA approval for the Powerlink AAA stent graft was received on October 29, 2004. The Powerlink superior design is covered by 17 U.S. patents with 361 allowed claims; the technology is designed to overcome shortcomings of first-generation ELGs. The device is for sale in the United States and selected international markets. Endologix is a publicly-held company trading on NASDAQ: ELGX. The company's corporate office is located in Irvine, California.

Endologix Headquarters Location

2 Musick

Irvine, California, 92618,

United States


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Endologix

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Endologix is included in 1 Expert Collection, including Medical Devices.


Medical Devices

905 items - excludes those without working websites.

Endologix Patents

Endologix has filed 79 patents.

The 3 most popular patent topics include:

  • Vascular diseases
  • Diseases of the aorta
  • Implants (medicine)
patents chart

Application Date

Grant Date


Related Topics




Vascular diseases, Arteries of the abdomen, Implants (medicine), Diseases of the aorta, Vascular surgery


Application Date


Grant Date



Related Topics

Vascular diseases, Arteries of the abdomen, Implants (medicine), Diseases of the aorta, Vascular surgery



Latest Endologix News

Endologix\'s AFX2 Endovascular AAA System Earns EU Nod

Aug 8, 2022

Certified under the new EU-MDR standard. Sam Brusco, Associate Editor08.08.22 Endologix has earned CE mark certification for its AFX2 endovascular AAA system under the new European Medical Devices Regulation (EU-MDR). “CE Mark certification under the new requirements is a high-bar and we are proud of this significant company achievement. Meeting the rigor of the new framework is an important milestone for our AFX2 System,” Elisa Hebb, Endologix’s EVP of Medical, Clinical, Regulatory Affairs and Quality told the press. “We believe AFX2 offers an innovative solution for AAA and continues to play a significant role in clinical practice due to its differentiated design features and the compendium of clinical evidence,” added Matt Thompson, president and CEO of Endologix, “We are committed to investing in clinical research to evaluate the long-term outcomes of our products. Evidence to date supports the comparative effectiveness of AFX2 in the treatment of patients with abdominal aneurysms.”   The AFX2 system was introduced in 2016, with comparative performance studied in the LEOPARD trial. The study compared AFX2 and its AFX predecessor to commercially available endografts. 5-year results will be released later this year. 4-year results showed freedom from aneurysm related complications was similar between AFX and AFX2 cohort and comparator endografts.

Endologix Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Endologix Rank

  • When was Endologix founded?

    Endologix was founded in 1992.

  • Where is Endologix's headquarters?

    Endologix's headquarters is located at 2 Musick, Irvine.

  • What is Endologix's latest funding round?

    Endologix's latest funding round is Take Private.

  • How much did Endologix raise?

    Endologix raised a total of $177.5M.

  • Who are the investors of Endologix?

    Investors of Endologix include Deerfield Management, Paycheck Protection Program, EW Healthcare Partners, Goldman Sachs, Epic Ventures and 6 more.

  • Who are Endologix's competitors?

    Competitors of Endologix include Monteris Medical, Reva Medical, MicroTransponder, Gynesonics, Vertos Medical, Svelte Medical Systems, Sequana Medical, Calibra Medical, ReShape Medical, Tryton Medical and 54 more.

You May Also Like

Varix Medical

Varix Medical Corporation, located in Sunnyvale, Calif., is a medical device company focused on developing products for the minimally invasive treatment of chronic venous insufficiency, commonly referred to as "varicose veins." For patients with advanced stages of varicose veins, laser- and RF-based (radiofrequency) treatments have been developed, but each device has deficiencies making them less-than-optimal solutions. Varix Medical's platform technology will enable physicians to efficiently and effectively treat more types of diseased veins than is currently possible when using either laser or RF devices. Additional treatable vessels include tortuous sub-truncal vessels and other visible smaller varicose veins. The Varix platform employs a vapor-based endovenous ablation system that will consist of a disposable catheter, a catheter introducer or delivery system, and a reusable vapor generator. RCT and Coronis Medical Ventures LLC., formed Varix in August 2007 and acquired the technology under license from Tsunami MedTech LLC. Coronis and RCT have been the primary in investors in Varix.


Satiety, Inc. is a medical device company focused on the development of less invasive devices for the treatment of obesity. Obesity is a global health problem, affecting 70 million people in the U.S. and 300 million worldwide, and growth of which is causing increases in obesity-related diseases such as diabetes, high blood pressure and cardiovascular disease. Obesity surgery has been shown to be the only long-term effective means of weight loss for morbidly obese patients. Satiety's first product, the TOGA System, enables physicians to perform a procedure similar to traditional restrictive obesity surgeries, but without surgical incisions. In this procedure, the TOGA System devices are inserted transorally (through the mouth) and are used to reduce the capacity of the stomach to give patients a feeling of fullness after a small meal. The procedure is intended to be safer and easier for patients to tolerate than conventional obesity surgery. Safety and effectiveness of the TOGA System are currently being evaluated in a multi-center U.S. Study and the system is not available for sale in the United States.

Intersect Partners

Intersect Partners is a California based medical devices company. The company primarily produces intragastric balloons, stent-like neurological medical devices, and associated minimally invasive drug delivery and device systems.

TriReme Medical

TriReme Medical is a privately held medical device company dedicated to the development, manufacturing, and commercialization of next generation percutaneous devices for the treatment of complex coronary and peripheral arterial disease. The company is focused on the US and the emerging Asian markets.

Axial Biotech

Axial Biotech, founded in 2002 by a group of spine surgeons and geneticists, is focused on the use of genetics and the development of minimally invasive fusionless devices to advance the diagnosis and treatment of diseases and deformities of the human spine. Axial is a company to pursue DNA-based pre-symptomatic and prognostic tests for common spinal conditions which will augment current clinical and surgical practices. In its initial genetic product development initiative, Axial has made progress towards the discovery of a location in the human genome that is associated with adolescent idiopathic scoliosis. In addition, Axial's founders have developed five motion preserving, fusionless surgical devices (including such device currently being implanted in humans) that have the promise of expanding the current treatable scoliosis patient population by a factor of ten. Axial intends to use its genetic intellectual property in the development of bio-mechanical devices, and to apply its gene discovery/product development methodology to other spinal diseases. Axial ( is located in Salt Lake City, Utah.


DuoCure offers intraluminal minimally invasive implantable device for treatment of obesity.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.